3M Company

(New York Stock Exchange)
Back to all articles
Bullish +65

What to Expect From 3M Company’s Next Quarterly Earnings Report

Analyst upgrade Company update Earnings report AI-generated analysis

📈 3M reported Q2 adjusted EPS of $2.40 and revenue of $6.5 billion, beating analyst expectations and prompting a stock price increase in July.

🚀 The company raised its full-year adjusted EPS guidance to $8.80–$8.95 with organic sales growth projected above 3.5% and operating margins expected at 24.9%.

⚖️ 3M faces substantial litigation liabilities, agreeing to pay up to $12.5 billion for PFAS claims and $6 billion for Combat Arms earplug disputes.

🔬 CEO William Brown highlighted improved operational efficiency with on-time deliveries rising to ~90% from the low-80% range.

📦 The company plans approximately 350 new product launches in 2026, aiming for new products to represent 20% of sales by end-2027.

💡 3M identifies expanded-beam optical technology as a key growth driver, expecting $400 million in incremental revenue from data center applications this year.

📊 Bernstein upgraded MMM to 'Market Perform' and raised its price target to $171, citing progress in R&D and reduced PFAS liability risks.

📉 Despite a 9.4% gain over the past 52 weeks, MMM stock has underperformed the S&P 500 (15.2%) and Industrials sector ETF (XLI) during the same period.

👥 Wall Street maintains a 'Moderate Buy' consensus rating with an average price target of $189.76, implying 12.6% upside from current levels.

🌍 3M operates through a global network spanning research, development, manufacturing, and distribution to serve diverse industries worldwide.

Bullish Signals
  • 3M topped Q2 analyst expectations with adjusted EPS of $2.40 and revenue of $6.5 billion, driving a stock price increase in July.
  • The company raised its full-year adjusted EPS guidance to $8.80–$8.95 and projected organic sales growth exceeding 3.5%.
  • Bernstein upgraded MMM to 'Market Perform' and increased its price target to $171, citing improved R&D execution and reduced PFAS liability risks.
  • CEO William Brown reported that on-time, in-full deliveries have improved to approximately 90%, indicating stronger operational performance.
  • 3M plans roughly 350 new product launches in 2026, with a strategic goal for new products to account for 20% of sales by end-2027.
  • The company expects expanded-beam optical technology to generate approximately $400 million in growth above underlying markets this year.
  • Analyst consensus remains positive with a 'Moderate Buy' rating and an average price target of $189.76, suggesting 12.6% upside potential.
Risk Factors
  • 3M has agreed to pay up to $12.5 billion to settle PFAS-related claims involving public water systems, creating a significant financial liability.
  • The company also faces up to $6 billion in settlement obligations for veterans' claims related to its Combat Arms earplugs.
  • Despite recent gains, MMM stock has lagged the broader market and industrial peers over the past 52 weeks, with a 9.4% gain versus 15.2% for the S&P 500.
  • Litigation remains a persistent concern weighing on investor sentiment, even as operational metrics show improvement.
Full Analysis
3M Company (MMM) is a diversified industrial conglomerate with a market capitalization of $87.4 billion, operating across healthcare, transportation, electronics, and consumer goods sectors. The company recently reported strong Q2 results with adjusted EPS of $2.40 and revenue of $6.5 billion, surpassing analyst expectations. This performance led to an upgrade from Bernstein, which raised its price target to $171 citing improved R&D progress and reduced PFAS liability risks. Looking ahead, Wall Street expects 3M's fiscal 2026 diluted EPS to reach $8.96, representing an 11.2% increase from the prior year, with further growth projected for fiscal 2027. The company has demonstrated operational resilience by improving on-time delivery rates to approximately 90% and planning roughly 350 new product launches in 2026. Management expects these new products to contribute 20% of total sales by the end of 2027, signaling a strategic shift toward innovation-driven revenue. Despite lingering concerns over significant litigation liabilities, including up to $12.5 billion for PFAS claims and $6 billion for Combat Arms earplugs, investors are increasingly focused on execution improvements. The stock has delivered a 9.4% gain over the past 52 weeks, though it still lags broader market indices. Analyst consensus remains positive with a 'Moderate Buy' rating and an average price target of $189.76, suggesting potential upside as the company navigates legal headwinds and capitalizes on new growth avenues like expanded-beam optical technology.